BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Loading...
Loading...

syndrome de kuver et bucy Pages on BioPortfolio:

BioPortfolio - Kluver-Bucy Syndrome
[Kluver-Bucy syndrome. Seven year follow-up of one patient] OBJECTIVE: To present a left-handed patient who had an acute... 20th May, 2008, Servicio de
...
http://www.bioportfolio.com/indepth/Kluver-Bucy_Syndrome.htm...

BioPortfolio - KlŸver-Bucy Syndrome research
Servicio de Neurologia Pediatrica, Hospital Universitario La Paz, Madrid. Kluver -Bucy syndrome following status epilepticus associated with hepatic ...
http://www.bioportfolio.com/indepth/Kl%C5%B8ver-Bucy_Syndrom...

BioPortfolio - the biotechnology, pharmaceutical, life science and ...
... Apollo_3.htm | macro-economic indicators health care china | Erectile Dysfunction Market | myelodysplastic syndrome drug development | Pharmaceutical
...
http://www.bioportfolio.com/bookshop/search/Kl%C5%B8ver-Bucy...

Biotechnology, Pharmaceutical and Life Science Email addresses for ...
BioPortfolio the comprehensive email list supplier for data, information, search engine and services on biotechnology, pharmaceutical and healthcare ...
http://www.bioportfolio.com/advertis/bioemail.htm...

Results from other life science and pharmaceutical sites:

BioPortfolio - Kluver-Bucy Syndrome
[Kluver-Bucy syndrome. Seven year follow-up of one patient] OBJECTIVE: To present a left-handed patient who had an acute... 20th May, 2008, Servicio de
...
http://www.bioportfolio.com/indepth/Kluver-Bucy_Syndrome.htm...

Analysis of prognostic factors for allogeneic marrow ...
myelodysplastic syndrome; BuCy; allogeneic transplantation .... 17 Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with ...
http://www.nature.com/bmt/journal/v25/n12/full/1702432a.html...

The critical early proinflammatory events associated with ...
Idiopathic pneumonia syndrome after bone marrow transplantation. .... [PubMed]; Panoskaltsis-Mortari A, Bucy RP. In situ hybridization with ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=50...

Bone marrow transplantation for myelodysplastic syndrome who? when ...
21 De Witte T, van Biezen A, Hermans J et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute
myeloid ...
http://www.nature.com/bmt/journal/v30/n4/full/1703610a.html...

References
Moreland LW, Bucy RP, Weinblatt ME, et al.: Immune function in patients with ... Zeckel ML: Histoplasmosis in the acquired immune deficiency syndrome. ...
http://www.medscape.com/content/2004/00/48/27/482792/482792_...

Bone Marrow Transplantation - Fludarabine and busulfan as a ...
Busulfan and cyclophosphamide (BuCy) are currently the most widely used ..... Cancer Center by de Lima et al.21 showed that 40 mg/m2 fludarabine and 130 ...
http://www.nature.com/bmt/journal/v40/n2/full/1705685a.html...

Processing the Facial Image: A Brief History
with the Klüver–Bucy syndrome and its fractionation and. then continuing with lesion and ..... isolée de la vision mentale des signes et des objets (formes
...
http://www.princeton.edu/~cggross/Am_Psychol_Face_2005.pdf...

Bone Marrow Transplantation - Fludarabine and busulfan as a ...
Busulfan and cyclophosphamide (BuCy) are currently the most widely used ..... came from MD Anderson Cancer Center by de Lima et al.21 showed that 40 mg/m2 ...
http://www.nature.com/bmt/journal/vaop/ncurrent/full/1705685...

[Extramedullary toxicity in bone marrow transplant...[Sangre (Barc ...
CONCLUSIONS: The toxicity of the BuCy conditioning regimen was lesser than ... from related or unrelated donors in patients with myelodysplastic syndrome. ...
http://www.ncbi.nlm.nih.gov/pubmed/7570271...

Autotransplantation following busulfan, etoposide and ...
BuCy2 is widely used and accepted as standard preparative therapy in NHL.30 ..... 40 Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after ...
http://www.nature.com/bmt/journal/v25/n12/full/1702433a.html...

Google Custom Search

Search
  

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo